Talazoparib

Talazoparib

SCHEMBL30953898

Cn1ncnc1[C@H]1c2n[nH]c(=O)c3cc(F)cc(c23)NC1c1ccc(F)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PARP1PARP2

The experimentally established mechanism targets of Talazoparib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
PARP1 known ✓ P09874 20/20 1.00
PARP2 known ✓ Q9UGN5 15/20 1.00
PARP3 Q9Y6F1 15/20 1.00
TNKS O95271 2/20 1.00
PARP10 Q53GL7 2/20 1.00
PARP16 Q8N5Y8 2/20 1.00
PARP4 Q9UKK3 2/20 1.00
PARP15 Q460N3 1/20 1.00
PARP14 Q460N5 1/20 1.00
TNKS2 Q9H2K2 1/20 1.00
PARP8 Q8N3A8 1/20 1.00
PARP11 Q9NR21 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Talazoparib SCHEMBL30099172 1.00 PARP1 (1.00) PARP1PARP2PARP3TNKSPARP10
Talazoparib SCHEMBL2299348 1.00 PARP1 (1.00) PARP1PARP2PARP3TNKSPARP10
Talazoparib SCHEMBL16204525 1.00 PARP1 (1.00) PARP1PARP2PARP3TNKSPARP10
Talazoparib SCHEMBL30099170 1.00 PARP1 (1.00) PARP1PARP2PARP3TNKSPARP10
Talazoparib SCHEMBL23048317 1.00 PARP1 (1.00) PARP1PARP2PARP3TNKSPARP10
Talazoparib SCHEMBL2046086 1.00 PARP1 (1.00) PARP1PARP2PARP3TNKSPARP10
Talazoparib SCHEMBL24440571 1.00 PARP1 (1.00) PARP1PARP2PARP3TNKSPARP10
Talazoparib SCHEMBL2295997 1.00 PARP1 (1.00) PARP1PARP2PARP3TNKSPARP10
Talazoparib SCHEMBL30419102 1.00 PARP1 (1.00) PARP1PARP2PARP3TNKSPARP10
Talazoparib SCHEMBL29948077 1.00 PARP1 (1.00) PARP1PARP2PARP3TNKSPARP10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240180962-A1 TREATMENT OF CANCER WITH NK CELLS AND A CD20 TARGETED ANTIBODY GC Cell Corporation (KR) 2024-06-06 US disclosed